Maha AlMolaiki was graduated from King Saud University(KSU) with Pharm.D. degree, an employee in King Abdulaziz Medical City-Central Region(KAMC-CR) since 2014, who assists in patient care, both in outpatient and inpatient settings, joined the pharmacy residency program in 2016, currently pharmacy resident. Had two publications.


Aim: to assess the likelihood of developing new-onset ischemic stroke among patients who were using PPIs for 6 months or more versus patients who were not using PPIs. 

Background: Stroke is a rapid loss of brain function due to disruption of blood supply to the brain and a major cause of mortality and morbidity worldwide. In Saudi Arabia, the incidence of ischemic strokes is 69%. The established risk factors are hypertension, diabetes mellitus, smoking, dyslipidemia. Proton pump inhibitors (PPIs) one of the world’s most frequently prescribed medications contributed to many adverse effects. In 2016, a retrospective study found a significant increase in the risk of new onset ischemic stroke in the PPIs users. In 2018, a prospective cohort study found no association.